Heinz-Herbert Fiebig

EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models.

J. Double, M. Bibby, H. Fiebig, 1993, European journal of cancer.

Preclinical phase II study of ifosfamide in human tumour xenografts in vivo

H. Fiebig, D. Berger, B. Winterhalter, 2004, Cancer Chemotherapy and Pharmacology.

BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin.

N. Farrell, F. Zunino, R. Supino, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Predicting tumor responses to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumor homogenates: implications for enzyme-directed bioreductive drug development.

P. Loadman, H. Fiebig, C. Jarrett, 2000, Cancer research.

Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells.

M. Grever, E. Sausville, H. Fiebig, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study.

O. Fodstad, S. Langdon, H. Fiebig, 1992, Cancer research.